MediPharm Labs (TSE:LABS)
TSX:LABS
Want to see TSE:LABS full AI Analyst Report?
LABS Stock Chart & Stats
C$0.08
<C$0.01(7.69%)
At close: 4:00 PM EST
C$0.08
<C$0.01(7.69%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.10
Previous CloseN/A
Volume690.59K
Average Volume (3M)466.64K
Market Cap
C$36.11M
Enterprise ValueC$24.14M
Total Cash (Recent Filing)C$9.87M
Total Debt (Recent Filing)C$18.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 17, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding424,864,260
10 Day Avg. Volume458,518
30 Day Avg. Volume466,636
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)C$38.98M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthMinimal debt and a conservatively financed balance sheet materially reduce refinancing and interest risks, giving management flexibility to fund operations, sustain working capital and pursue selective partnerships or M&A while markets recover, supporting multi‑month resilience.
High Gross MarginSustained 37% gross margin and demonstrated cost discipline (opex reductions and restructuring) indicate the company can protect unit economics. Strong gross margins improve the pathway from adjusted EBITDA to operating profitability even if volumes remain pressured over several quarters.
International & Pharma OptionalityDiversified international commercial traction (France, Brazil, New Zealand, Germany growth) reduces reliance on domestic demand. Coupled with pharma‑grade regulatory credentials, this supports durable B2B, contract manufacturing and potential API/pharma research opportunities over time.
Bears Say
Negative Cash FlowNegative trailing‑twelve‑month operating and free cash flow mean the business is consuming capital rather than self‑funding growth. Continued cash burn limits strategic optionality, may force external financing if losses persist, and elevates liquidity risk across multiple quarters.
Revenue Decline & Category WeaknessPersistent top‑line weakness and a contracting adult‑use/wellness category reduce utilization of extraction capacity and constrain organic revenue recovery. Structural volume pressure makes margin and profit improvement more dependent on mix shifts than on volume growth in the near term.
Reimbursement & Regulatory UncertaintyCuts to reimbursement rates and ongoing regulatory/timing uncertainty place durable margin pressure on the Canadian medical channel. Delays in local import authorizations and approvals can push revenue recognition later, increasing multi‑quarter volatility in cash flows and profitability.
MediPharm Labs News
LABS FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was C$0.06 and its highest was C$0.10 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is C$36.11M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Aug 17, 2026 which is in 88 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on May 13, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.003 by C$0.003.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 424,864,260 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.003. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in TSE:LABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.
LABS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear near-term challenges—most notably a ~16.7% YoY revenue decline, a widened net loss and industry reimbursement headwinds—with several material positives: return to positive adjusted EBITDA, a strong 37% gross margin, meaningful operating expense reductions (‑14% YoY, ‑28% sequential), $1.0M in expected annualized savings, $9.9M cash and limited debt, and continued international commercial traction (France, New Zealand, Brazil, Germany). Management emphasizes disciplined, margin-focused execution and long-term pharma optionality supported by rare regulatory credentials. Given the company's demonstrated ability to protect margins, improve profitability metrics and maintain liquidity while advancing international expansion, the tone is cautiously optimistic.View all TSE:LABS earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---